 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 April 1997 | Volume 126 Issue 7 | Pages 528-531
Background: Previous reports suggest that younger carriers of the factor V Leiden mutation are at greater risk for venous thromboembolism than are older carriers. However, available data on thromboembolic risk are limited.
Objective: To determine age-specific incidence rates of venous thromboembolism associated with the factor V Leiden mutation.
Design: Prospective cohort study.
Patients: 14 916 initially healthy men participating in the Physicians' Health Study who were followed from 1982 to August 1994 for the occurrence of deep venous thrombosis or pulmonary embolism.
Measurements: Polymerase chain reaction was used to determine factor V Leiden mutation status in 156 study participants who developed venous thromboembolism during follow-up and in 2406 study participants who remained free of vascular disease.
Results: Risks for venous thromboembolism in heterozygous carriers of factor V Leiden mutation increased with age at a rate significantly greater than that in noncarriers. Whereas incidence rates of venous thromboembolism were similar in men with and men without the factor V Leiden mutation who were younger than 50 years of age, incidence rate differences (per 1000 person-years of observation) between affected and unaffected men increased significantly from 1.23 (95% CI, –0.4 to 2.9) for those aged 50 to 59 years to 1.61 (CI, –0.5 to 3.7) for those aged 60 to 69 years of age to 5.97 (CI, 0.6 to 11.3) for those aged 70 years or older (P for trend = 0.008). For idiopathic venous thromboembolism, age-specific incidence rate differences between men with and without the factor V Leiden mutation increased significantly with age (P = 0.017). However, no significant relation was found for secondary events (P > 0.2).
Conclusions: The findings support the hypothesis that the pathogenesis of venous thromboembolism involves acquired as well as genetic risk factors and indicate that determination of factor V Leiden mutation status should not be limited to young patients.
Author and Article Information
For author affiliations and current author addresses, see end of text.
BRIEF COMMUNICATION
Age-Specific Incidence Rates of Venous Thromboembolism among Heterozygous Carriers of Factor V Leiden Mutation
Grant Support: In part by a Clinician Scientist Award from the American Heart Association (Dr. Ridker) and by grants HL-26490, HL-34595, CA-42182, and CA-40361 from the National Institutes of Health, Bethesda, Maryland.
Requests for Reprints: Paul M. Ridker, MD, Department of Medicine, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, MA 02115.
Current Author Addresses: Drs. Ridker and Goldhaber: Division of Cardiovascular Disease, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02215.
This article has been cited by other articles:
|
|
 |
|
  J. A. Heit Thrombophilia: Common Questions on Laboratory Assessment and Management Hematology, January 1, 2007; 2007(1): 127 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Girolami, L. Spiezia, B. Girolami, N. Zocca, and G. Luzzatto Effect of Age on Oral Contraceptive-Induced Venous Thrombosis Clinical and Applied Thrombosis/Hemostasis, July 1, 2004; 10(3): 259 - 263. [Abstract] [PDF]
|
|
|
|
 |
|
 Z Szolnoki, F Somogyvari, A Kondacs, M Szabo, L Fodor, J Bene, and B Melegh Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke J. Neurol. Neurosurg. Psychiatry, December 1, 2003; 74(12): 1615 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Anderson Jr. and F. A. Spencer Risk Factors for Venous Thromboembolism Circulation, June 17, 2003; 107(90231): I-9 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Abramson and R. H. Aster Retrospective Assessment of Hypercoagulability in Breast Cancer Prevention Trial J. Clin. Oncol., October 1, 2002; 20(19): 4133 - 4134. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Herrington, E. Vittinghoff, T. D. Howard, D. A. Major, J. Owen, D. M. Reboussin, D. Bowden, V. Bittner, J. A. Simon, D. Grady, et al. Factor V Leiden, Hormone Replacement Therapy, and Risk of Venous Thromboembolic Events in Women With Coronary Disease Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 1012 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. V Joffe and S. Z Goldhaber Laboratory thrombophilias and venous thromboembolism Vascular Medicine, May 1, 2002; 7(2): 93 - 102. [Abstract] [PDF]
|
|
|
|
 |
|
 A. R. Folsom, M. Cushman, M. Y. Tsai, N. Aleksic, S. R. Heckbert, L. L. Boland, A. W. Tsai, N. D. Yanez, and W. D. Rosamond A prospective study of venous thromboembolism in relation to factor V Leiden and related factors Blood, April 15, 2002; 99(8): 2720 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Herrington and K. P. Klein Genome and Hormones: Gender Differences in Physiology: Invited Review: Pharmacogenetics of estrogen replacement therapy J Appl Physiol, December 1, 2001; 91(6): 2776 - 2784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Middeldorp, J. R. Meinardi, M. M.W. Koopman, E. C.M. van Pampus, K. Hamulyak, J. van der Meer, M. H. Prins, and H. R. Buller A Prospective Study of Asymptomatic Carriers of the Factor V Leiden Mutation To Determine the Incidence of Venous Thromboembolism Ann Intern Med, September 4, 2001; 135(5): 322 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Heron, O. Lozinguez, M. Alhenc-Gelas, J. Emmerich, and J.-N. Fiessinger Hypercoagulable States in Primary Upper-Extremity Deep Vein Thrombosis Arch Intern Med, February 14, 2000; 160(3): 382 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.H. van Boven, J.P. Vandenbroucke, E. Briet, and F.R. Rosendaal Gene-Gene and Gene-Environment Interactions Determine Risk of Thrombosis in Families With Inherited Antithrombin Deficiency Blood, October 15, 1999; 94(8): 2590 - 2594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bucciarelli, F. R. Rosendaal, A. Tripodi, P. M. Mannucci, V. De Stefano, G. Palareti, G. Finazzi, F. Baudo, and R. Quintavalla Risk of Venous Thromboembolism and Clinical Manifestations in Carriers of Antithrombin, Protein C, Protein S Deficiency, or Activated Protein C Resistance : A Multicenter Collaborative Family Study Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 1026 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. MURIN, G. P. MARELICH, A. C. ARROLIGA, and R. A. MATTHAY Hereditary Thrombophilia and Venous Thromboembolism Am. J. Respir. Crit. Care Med., November 1, 1998; 158(5): 1369 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker and PREVENT Investigators Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial Vascular Medicine, February 1, 1998; 3(1): 67 - 73. [Abstract] [PDF]
|
|
|
|
 |
|
 F. P Sarasin and H. Bounameaux Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis BMJ, January 10, 1998; 316(7125): 95 - 99. [Abstract] [Full Text]
|
|
|
|
 |
|
 Factor V Leiden Risk Not Limited to Young Patients Journal Watch Cardiology, April 28, 1997; 1997(428): 13 - 13. [Full Text]
|
|
Article
